The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] promotes the reaction [Silver Compounds results in decreased expression of ALOX15 mRNA]]
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid results in decreased expression of ALOX5 protein 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[[Dietary Fats co-treated with Cholesterol, Dietary] results in increased susceptibility to Silver Compounds] which results in decreased expression of ALOX5 mRNA]
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] promotes the reaction [Silver Compounds results in increased expression of CCL2 mRNA]]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] promotes the reaction [Silver Compounds results in increased expression of CCL2 protein]]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Silver Compounds results in increased susceptibility to [Dietary Fats co-treated with Cholesterol, Dietary]] which results in increased expression of CCL2 mRNA]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Silver Compounds results in increased susceptibility to [Dietary Fats co-treated with Cholesterol, Dietary]] which results in increased expression of CCL2 protein]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL2 protein]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Silver Compounds results in increased expression of CCL2 mRNA]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Silver Compounds results in increased expression of CCL2 protein]
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] promotes the reaction [Silver Compounds results in increased expression of CXCL2 mRNA]]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] promotes the reaction [Silver Compounds results in increased expression of CXCL2 protein]]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Silver Compounds results in increased susceptibility to [Dietary Fats co-treated with Cholesterol, Dietary]] which results in increased expression of CXCL2 mRNA]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Silver Compounds results in increased susceptibility to [Dietary Fats co-treated with Cholesterol, Dietary]] which results in increased expression of CXCL2 protein]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of CXCL2 protein]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Silver Compounds results in increased expression of CXCL2 mRNA]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Silver Compounds results in increased expression of CXCL2 protein]; [Silver Compounds results in increased susceptibility to 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid] which results in increased expression of CXCL2 mRNA
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] promotes the reaction [Silver Compounds results in increased expression of IL6 mRNA]]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] promotes the reaction [Silver Compounds results in increased expression of IL6 protein]]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Silver Compounds results in increased susceptibility to [Dietary Fats co-treated with Cholesterol, Dietary]] which results in increased expression of IL6 mRNA]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Silver Compounds results in increased susceptibility to [Dietary Fats co-treated with Cholesterol, Dietary]] which results in increased expression of IL6 protein]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Silver Compounds results in increased expression of IL6 mRNA]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Silver Compounds results in increased expression of IL6 protein]
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased activity of MPO protein]
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein] 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid results in decreased secretion of TNF protein
[[Oxygen deficiency results in increased activity of ALOX15 protein] which results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid] which results in decreased expression of KCNA5 mRNA; [[Oxygen deficiency results in increased activity of ALOX15 protein] which results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid] which results in decreased expression of KCNA5 protein; [Oxygen deficiency results in increased activity of ALOX15 protein] which results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid; cinnamyl-3,4-dihydroxycyanocinnamate inhibits the reaction [[[Oxygen deficiency results in increased activity of ALOX15 protein] which results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid] which results in decreased expression of KCNA5 mRNA]; Masoprocol inhibits the reaction [[[Oxygen deficiency results in increased activity of ALOX15 protein] which results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid] which results in decreased expression of KCNA5 mRNA] ALOX15 protein results in increased abundance of 15-hydroxy-5,8,11,13-eicosatetraenoic acid [ALOX15 protein affects the metabolism of Arachidonic Acid] which results in increased abundance of 15-hydroxy-5,8,11,13-eicosatetraenoic acid ALOX15 protein results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid
[benoxaprofen results in decreased activity of ALOX5 protein] which results in increased abundance of 15-hydroxy-5,8,11,13-eicosatetraenoic acid; [Masoprocol results in decreased activity of ALOX5 protein] which results in increased abundance of 15-hydroxy-5,8,11,13-eicosatetraenoic acid; [RS 43179 results in decreased activity of ALOX5 protein] which results in increased abundance of 15-hydroxy-5,8,11,13-eicosatetraenoic acid; [tenidap results in decreased activity of ALOX5 protein] which results in increased abundance of 15-hydroxy-5,8,11,13-eicosatetraenoic acid
APP protein modified form results in increased secretion of 15-hydroxy-5,8,11,13-eicosatetraenoic acid CNB 001 inhibits the reaction [APP protein modified form results in increased secretion of 15-hydroxy-5,8,11,13-eicosatetraenoic acid]; Dronabinol inhibits the reaction [APP protein modified form results in increased secretion of 15-hydroxy-5,8,11,13-eicosatetraenoic acid]; L 685458 inhibits the reaction [APP protein modified form results in increased secretion of 15-hydroxy-5,8,11,13-eicosatetraenoic acid]
15-hydroxy-5,8,11,13-eicosatetraenoic acid promotes the reaction [EGF protein affects the localization of PRKCA protein] EGF protein results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid
15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of IL1B protein IL1B protein affects the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]; IL1B protein affects the reaction [TNF protein affects the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]]; TNF protein affects the reaction [IL1B protein affects the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]]
[[Oxygen deficiency results in increased activity of ALOX15 protein] which results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid] which results in decreased expression of KCNA5 mRNA; [[Oxygen deficiency results in increased activity of ALOX15 protein] which results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid] which results in decreased expression of KCNA5 protein; cinnamyl-3,4-dihydroxycyanocinnamate inhibits the reaction [[[Oxygen deficiency results in increased activity of ALOX15 protein] which results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid] which results in decreased expression of KCNA5 mRNA]; Masoprocol inhibits the reaction [[[Oxygen deficiency results in increased activity of ALOX15 protein] which results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid] which results in decreased expression of KCNA5 mRNA] 15-hydroxy-5,8,11,13-eicosatetraenoic acid affects the activity of KCNA5 protein
15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein [parthenolide co-treated with artemisinin co-treated with Quercetin] inhibits the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]; artemisinin inhibits the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]; IL1B protein affects the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]; IL1B protein affects the reaction [TNF protein affects the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]]; parthenolide inhibits the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]; Quercetin inhibits the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]; SB 203580 inhibits the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]; TNF protein affects the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]; TNF protein affects the reaction [IL1B protein affects the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]]
15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased activity of NFKB1 protein 15-hydroxy-5,8,11,13-eicosatetraenoic acid affects the localization of NFKB1 protein artemisinin inhibits the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid affects the localization of NFKB1 protein]
15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased phosphorylation of and results in increased degradation of NFKBIA protein; calphostin C inhibits the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased phosphorylation of and results in increased degradation of NFKBIA protein] 15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased phosphorylation of and results in increased degradation of NFKBIA protein; Quercetin inhibits the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased phosphorylation of and results in increased degradation of NFKBIA protein]
15-hydroxy-5,8,11,13-eicosatetraenoic acid promotes the reaction [EGF protein affects the localization of PRKCA protein]; 15-hydroxy-5,8,11,13-eicosatetraenoic acid promotes the reaction [HGF protein affects the localization of PRKCA protein] calphostin C inhibits the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased activity of PRKCA protein] 15-hydroxy-5,8,11,13-eicosatetraenoic acid affects the localization of PRKCA protein
15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased activity of RELA protein artemisinin inhibits the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid affects the localization of RELA protein]
IL1B protein affects the reaction [TNF protein affects the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]]; TNF protein affects the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]; TNF protein affects the reaction [IL1B protein affects the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]] 15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of TNF protein
[PTGS1 protein results in increased metabolism of Arachidonic Acid] which results in increased chemical synthesis of 12-hydroxy-5,8,10-heptadecatrienoic acid; arzanol inhibits the reaction [[PTGS1 protein results in increased metabolism of Arachidonic Acid] which results in increased chemical synthesis of 12-hydroxy-5,8,10-heptadecatrienoic acid]
[Sulfasalazine results in decreased activity of TBXAS1 protein] which results in decreased chemical synthesis of 12-hydroxy-5,8,10-heptadecatrienoic acid
20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of ACTA2 mRNA; 20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of ACTA2 protein 20-hydroxyeicosa-5(Z),14(Z)-dienoic acid promotes the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of ACTA2 mRNA]; 20-hydroxyeicosa-5(Z),14(Z)-dienoic acid promotes the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of ACTA2 protein]; 20-hydroxyeicosa-6(Z),15(Z)-dienoic acid inhibits the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of ACTA2 mRNA]; 20-hydroxyeicosa-6(Z),15(Z)-dienoic acid inhibits the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of ACTA2 protein]
20-hydroxyeicosa-5(Z),14(Z)-dienoic acid promotes the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of COL1A1 mRNA]; 20-hydroxyeicosa-5(Z),14(Z)-dienoic acid promotes the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of COL1A1 protein]; 20-hydroxyeicosa-6(Z),15(Z)-dienoic acid inhibits the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of COL1A1 mRNA]; 20-hydroxyeicosa-6(Z),15(Z)-dienoic acid inhibits the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of COL1A1 protein] 20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of COL1A1 mRNA; 20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of COL1A1 protein
20-hydroxy-5,8,11,14-eicosatetraenoic acid affects the reaction [CYP4A1 protein affects the susceptibility to Phenylephrine]; 20-hydroxy-5,8,11,14-eicosatetraenoic acid inhibits the reaction [DDMS inhibits the reaction [CYP4A1 protein results in increased susceptibility to Phenylephrine]] CYP4A1 protein results in increased chemical synthesis of 20-hydroxy-5,8,11,14-eicosatetraenoic acid
Cyclosporine inhibits the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased localization of NFATC4 protein]; Tacrolimus inhibits the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased localization of NFATC4 protein]
HET0016 inhibits the reaction [POMC protein affects the abundance of 20-hydroxy-5,8,11,14-eicosatetraenoic acid] POMC protein results in increased abundance of 20-hydroxy-5,8,11,14-eicosatetraenoic acid
20-hydroxyeicosa-5(Z),14(Z)-dienoic acid promotes the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased phosphorylation of SMAD3 protein]; 20-hydroxyeicosa-6(Z),15(Z)-dienoic acid inhibits the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased phosphorylation of SMAD3 protein]
20-hydroxyeicosa-5(Z),14(Z)-dienoic acid promotes the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of TGFB1 mRNA]; 20-hydroxyeicosa-5(Z),14(Z)-dienoic acid promotes the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of TGFB1 protein]; 20-hydroxyeicosa-6(Z),15(Z)-dienoic acid inhibits the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of TGFB1 mRNA]; 20-hydroxyeicosa-6(Z),15(Z)-dienoic acid inhibits the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of TGFB1 protein] 20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of TGFB1 mRNA; 20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of TGFB1 protein
3-Hydroxybutyric Acid affects the reaction [ZFP36 protein affects the reaction [1-Methyl-4-phenylpyridinium results in increased expression of ACSL4 protein]]; 3-Hydroxybutyric Acid inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ACSL4 protein]; 3-Hydroxybutyric Acid inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of ACSL4 protein]
3-Hydroxybutyric Acid inhibits the reaction [Rotenone results in increased activity of CASP3 protein] 3-Hydroxybutyric Acid promotes the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of CASP3 protein]
3-Hydroxybutyric Acid promotes the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of CASP8 protein]
3-Hydroxybutyric Acid inhibits the reaction [Rotenone results in increased activity of CASP9 protein] 3-Hydroxybutyric Acid promotes the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of CASP9 protein]
3-Hydroxybutyric Acid inhibits the reaction [ERCC6 gene mutant form results in decreased abundance of Acetyl Coenzyme A]; 3-Hydroxybutyric Acid inhibits the reaction [ERCC6 gene mutant form results in decreased expression of SIRT1 protein]; 3-Hydroxybutyric Acid inhibits the reaction [ERCC6 gene mutant form results in decreased expression of UCP2 protein]; 3-Hydroxybutyric Acid inhibits the reaction [ERCC6 gene mutant form results in increased abundance of Superoxides]; 3-Hydroxybutyric Acid inhibits the reaction [ERCC6 gene mutant form results in increased acetylation of TP53 protein]; 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [3-Hydroxybutyric Acid inhibits the reaction [ERCC6 gene mutant form results in increased abundance of Superoxides]] ERCC6 gene mutant form results in decreased abundance of 3-Hydroxybutyric Acid Dietary Fats inhibits the reaction [ERCC6 gene mutant form results in decreased abundance of 3-Hydroxybutyric Acid]
3-Hydroxybutyric Acid results in decreased activity of FFAR3 protein 3-Hydroxybutyric Acid inhibits the reaction [3-(indol-3-yl)propionic acid results in increased activity of FFAR3 protein]
3-Hydroxybutyric Acid affects the reaction [ZFP36 protein affects the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of FTH1 protein]]; 3-Hydroxybutyric Acid inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of FTH1 protein]; 3-Hydroxybutyric Acid inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of FTH1 protein]
3-Hydroxybutyric Acid promotes the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of GPT protein]
3-Hydroxybutyric Acid affects the reaction [ZFP36 protein affects the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of GPX4 protein]]; 3-Hydroxybutyric Acid inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GPX4 protein]; 3-Hydroxybutyric Acid inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of GPX4 protein]
3-Hydroxybutyric Acid results in increased activity of HCAR2 protein 3-Hydroxybutyric Acid binds to and results in increased activity of HCAR2 protein; [3-Hydroxybutyric Acid results in increased activity of HCAR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]
3-Hydroxybutyric Acid promotes the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of IL6 protein]
3-Hydroxybutyric Acid inhibits the reaction [SNCA protein results in increased susceptibility to Rotenone]; 3-Hydroxybutyric Acid promotes the reaction [ursodoxicoltaurine inhibits the reaction [SNCA protein results in increased susceptibility to Rotenone]] 3-Hydroxybutyric Acid affects the reaction [ZFP36 protein affects the reaction [1-Methyl-4-phenylpyridinium results in increased expression of SNCA protein]]; 3-Hydroxybutyric Acid inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SNCA protein]; 3-Hydroxybutyric Acid inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of SNCA protein]
3-Hydroxybutyric Acid affects the reaction [ZFP36 protein affects the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of TH protein]]; 3-Hydroxybutyric Acid inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH protein]; 3-Hydroxybutyric Acid inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of TH protein]
3-Hydroxybutyric Acid promotes the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of TNF protein]
3-Hydroxybutyric Acid affects the reaction [ZFP36 protein affects the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of FTH1 protein]]; 3-Hydroxybutyric Acid affects the reaction [ZFP36 protein affects the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of GPX4 protein]]; 3-Hydroxybutyric Acid affects the reaction [ZFP36 protein affects the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of TH protein]]; 3-Hydroxybutyric Acid affects the reaction [ZFP36 protein affects the reaction [1-Methyl-4-phenylpyridinium results in increased expression of ACSL4 protein]]; 3-Hydroxybutyric Acid affects the reaction [ZFP36 protein affects the reaction [1-Methyl-4-phenylpyridinium results in increased expression of SNCA protein]]; 3-Hydroxybutyric Acid inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of ZFP36 mRNA]; 3-Hydroxybutyric Acid inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of ZFP36 protein]
ALDH5A1 mutant form results in increased abundance of 4-hydroxybutyric acid ALDH5A1 gene mutant form results in increased abundance of 4-hydroxybutyric acid
[EPHX3 gene mutant form results in decreased hydrolysis of Epoxy Compounds] results in decreased abundance of [9,10,13-trihydroxy-11-octadecenoic acid binds to Ceramides]; [EPHX3 gene mutant form results in decreased hydrolysis of Epoxy Compounds] which results in decreased chemical synthesis of 9,10,13-trihydroxy-11-octadecenoic acid
Castor Oil results in increased expression of PAFAH1B1 protein isosorbide-5-mononitrate inhibits the reaction [Castor Oil results in increased expression of PAFAH1B1 protein]
leptomycin B inhibits the reaction [EGF protein results in increased phosphorylation of AKT1 protein]; leptomycin B inhibits the reaction [Formaldehyde affects the phosphorylation of AKT1 protein]; leptomycin B inhibits the reaction [Gefitinib results in decreased phosphorylation of AKT1 protein] leptomycin B results in increased phosphorylation of AKT1 protein
leptomycin B affects the localization of BACH1 protein leptomycin B inhibits the reaction [Cannabidiol results in decreased expression of BACH1 protein] leptomycin B inhibits the reaction [Cadmium Chloride affects the localization of BACH1 protein]; leptomycin B inhibits the reaction [Cadmium results in decreased activity of BACH1 protein]
[epigallocatechin gallate co-treated with leptomycin B] results in decreased expression of BIRC5 mRNA; [epigallocatechin gallate co-treated with leptomycin B] results in decreased expression of BIRC5 protein; [leptomycin B co-treated with TP53 gene mutant form] results in increased expression of BIRC5 mRNA; leptomycin B promotes the reaction [gefitinib results in decreased expression of BIRC5 protein]; TP53 gene mutant form inhibits the reaction [leptomycin B results in decreased expression of BIRC5 protein] leptomycin B results in decreased expression of BIRC5 mRNA; leptomycin B results in decreased expression of BIRC5 protein
[leptomycin B co-treated with TP53 gene mutant form] results in decreased expression of BRCA1 mRNA leptomycin B results in decreased expression of BRCA1 mRNA
leptomycin B results in increased secretion of CCL2 protein polydatin inhibits the reaction [leptomycin B results in increased secretion of CCL2 protein]
[epigallocatechin gallate co-treated with leptomycin B] results in increased expression of CDKN1A mRNA; [epigallocatechin gallate co-treated with leptomycin B] results in increased expression of CDKN1A protein; leptomycin B inhibits the reaction [gefitinib results in decreased expression of CDKN1A protein]; TP53 gene mutant form inhibits the reaction [leptomycin B results in increased expression of CDKN1A protein] leptomycin B results in increased expression of CDKN1A mRNA; leptomycin B results in increased expression of CDKN1A protein
leptomycin B results in decreased secretion of CXCL10 protein acteoside promotes the reaction [leptomycin B results in decreased secretion of CXCL10 protein]; Quercetin promotes the reaction [leptomycin B results in decreased secretion of CXCL10 protein]
leptomycin B results in increased expression of CYP3A4 mRNA [epigallocatechin gallate co-treated with leptomycin B] results in increased expression of CYP3A4 mRNA
[leptomycin B co-treated with TP53 gene mutant form] results in decreased expression of DNMT1 mRNA leptomycin B results in decreased expression of DNMT1 mRNA
leptomycin B inhibits the reaction [EGF protein affects the localization of SET protein alternative form]; leptomycin B inhibits the reaction [EGF protein results in increased phosphorylation of AKT1 protein]
leptomycin B results in increased expression of GPX1 mRNA [epigallocatechin gallate co-treated with leptomycin B] results in increased expression of GPX1 mRNA
leptomycin B results in increased phosphorylation of MAPK1 protein leptomycin B inhibits the reaction [gefitinib results in decreased phosphorylation of MAPK1 protein]
leptomycin B inhibits the reaction [gefitinib results in decreased phosphorylation of MAPK3 protein] leptomycin B results in increased phosphorylation of MAPK3 protein
leptomycin B affects the localization of RANBP1 protein leptomycin B inhibits the reaction [Phenylephrine affects the localization of and affects the expression of RANBP1 protein]
leptomycin B affects the reaction [Formaldehyde affects the localization of SET protein alternative form]; leptomycin B inhibits the reaction [EGF protein affects the localization of SET protein alternative form]
leptomycin B inhibits the reaction [arsenite inhibits the reaction [TGFB2 protein affects the localization of SMAD2 protein]]; leptomycin B inhibits the reaction [arsenite inhibits the reaction [XPO4 protein results in increased export of SMAD2 protein]]; leptomycin B inhibits the reaction [monomethylarsonous acid inhibits the reaction [TGFB2 protein affects the localization of SMAD2 protein]]; leptomycin B inhibits the reaction [monomethylarsonous acid inhibits the reaction [XPO4 protein results in increased export of SMAD2 protein]]
leptomycin B inhibits the reaction [arsenite inhibits the reaction [TGFB2 protein affects the localization of SMAD3 protein]]; leptomycin B inhibits the reaction [arsenite inhibits the reaction [XPO4 protein results in increased export of SMAD3 protein]]; leptomycin B inhibits the reaction [monomethylarsonous acid inhibits the reaction [TGFB2 protein affects the localization of SMAD3 protein]]; leptomycin B inhibits the reaction [monomethylarsonous acid inhibits the reaction [XPO4 protein results in increased export of SMAD3 protein]]
leptomycin B results in increased expression of SOD2 mRNA [epigallocatechin gallate co-treated with leptomycin B] results in increased expression of SOD2 mRNA
leptomycin B inhibits the reaction [arsenite inhibits the reaction [TGFB2 protein affects the localization of SMAD2 protein]]; leptomycin B inhibits the reaction [arsenite inhibits the reaction [TGFB2 protein affects the localization of SMAD3 protein]]; leptomycin B inhibits the reaction [monomethylarsonous acid inhibits the reaction [TGFB2 protein affects the localization of SMAD2 protein]]; leptomycin B inhibits the reaction [monomethylarsonous acid inhibits the reaction [TGFB2 protein affects the localization of SMAD3 protein]]
3,4,5,3',4'-pentachlorobiphenyl inhibits the reaction [leptomycin B results in increased expression of TP53 protein]; [leptomycin B co-treated with TP53 gene mutant form] results in decreased expression of BRCA1 mRNA; [leptomycin B co-treated with TP53 gene mutant form] results in decreased expression of CHEK2 mRNA; [leptomycin B co-treated with TP53 gene mutant form] results in decreased expression of DNMT1 mRNA; [leptomycin B co-treated with TP53 gene mutant form] results in decreased expression of HK2 mRNA; [leptomycin B co-treated with TP53 gene mutant form] results in decreased expression of MDM4 mRNA; [leptomycin B co-treated with TP53 gene mutant form] results in decreased expression of PRKCA mRNA; [leptomycin B co-treated with TP53 gene mutant form] results in decreased expression of TP63 mRNA; [leptomycin B co-treated with TP53 gene mutant form] results in increased expression of APAF1 mRNA; [leptomycin B co-treated with TP53 gene mutant form] results in increased expression of BIRC5 mRNA; [leptomycin B co-treated with TP53 gene mutant form] results in increased expression of IL6 mRNA; [leptomycin B co-treated with TP53 gene mutant form] results in increased expression of NFKB1 mRNA; [leptomycin B co-treated with TP53 gene mutant form] results in increased expression of TNFRSF10D mRNA; [sodium arsenite co-treated with leptomycin B] results in increased phosphorylation of TP53 protein; leptomycin B affects the localization of and results in decreased degradation of TP53 protein; leptomycin B inhibits the reaction [Cycloheximide results in increased degradation of TP53 protein]; leptomycin B inhibits the reaction [sodium arsenite affects the localization of TP53 protein]; leptomycin B inhibits the reaction [sodium arsenite results in increased degradation of TP53 protein mutant form]; leptomycin B inhibits the reaction [TP53 protein results in increased susceptibility to trichostatin A]; PCB 180 promotes the reaction [leptomycin B results in increased expression of TP53 protein]; Pravastatin inhibits the reaction [leptomycin B results in decreased degradation of TP53 protein]; TP53 gene mutant form inhibits the reaction [leptomycin B results in decreased expression of BIRC5 protein]; TP53 gene mutant form inhibits the reaction [leptomycin B results in increased expression of CDKN1A protein] TP53 gene mutant form results in increased susceptibility to leptomycin B alpha-naphthoflavone inhibits the reaction [Tetrachlorodibenzodioxin inhibits the reaction [leptomycin B results in increased expression of TP53 protein]]; Tetrachlorodibenzodioxin inhibits the reaction [leptomycin B results in increased expression of TP53 protein] leptomycin B affects the expression of TP53 protein
[leptomycin B co-treated with TP53 gene mutant form] results in decreased expression of TP63 mRNA leptomycin B results in decreased expression of TP63 mRNA
leptomycin B results in increased expression of TXNDC5 mRNA 1,1-bis(3'-indolyl)-1-(4-hydroxyphenyl)methane inhibits the reaction [leptomycin B results in increased expression of TXNDC5 mRNA]
leptomycin B results in decreased activity of XPO1 protein [leptomycin B results in decreased activity of XPO1 protein] which results in decreased export of SMAD4 protein
leptomycin B inhibits the reaction [arsenite inhibits the reaction [XPO4 protein results in increased export of SMAD2 protein]]; leptomycin B inhibits the reaction [arsenite inhibits the reaction [XPO4 protein results in increased export of SMAD3 protein]]; leptomycin B inhibits the reaction [monomethylarsonous acid inhibits the reaction [XPO4 protein results in increased export of SMAD2 protein]]; leptomycin B inhibits the reaction [monomethylarsonous acid inhibits the reaction [XPO4 protein results in increased export of SMAD3 protein]]
ALOX5 protein results in increased secretion of Leukotriene B4 ALOX5 protein results in increased chemical synthesis of Leukotriene B4 [benoxaprofen results in decreased activity of ALOX5 protein] which results in decreased chemical synthesis of Leukotriene B4; [Hydrogen Peroxide results in increased activity of ALOX5 protein] which results in increased chemical synthesis of Leukotriene B4; [Masoprocol results in decreased activity of ALOX5 protein] which results in decreased chemical synthesis of Leukotriene B4; [RS 43179 results in decreased activity of ALOX5 protein] which results in decreased chemical synthesis of Leukotriene B4; [Tamoxifen results in increased expression of ALOX5 protein] which results in increased abundance of Leukotriene B4; [tenidap results in decreased activity of ALOX5 protein] which results in decreased chemical synthesis of Leukotriene B4; [zileuton results in decreased activity of ALOX5 protein] which results in decreased abundance of Leukotriene B4; ALOX5 protein promotes the reaction [lipopolysaccharide, E. coli O26-B6 results in increased abundance of Leukotriene B4]; ALOX5 protein results in increased susceptibility to [Histamine results in increased abundance of Leukotriene B4]; kaempferol inhibits the reaction [ALOX5 protein results in increased chemical synthesis of Leukotriene B4]; Luteolin inhibits the reaction [ALOX5 protein results in increased chemical synthesis of Leukotriene B4]; quercetin 3'-sulfate inhibits the reaction [ALOX5 protein results in increased chemical synthesis of Leukotriene B4]; quercetin 3-O-glucuronide inhibits the reaction [ALOX5 protein results in increased chemical synthesis of Leukotriene B4]; Quercetin inhibits the reaction [ALOX5 protein results in increased chemical synthesis of Leukotriene B4]; Resveratrol inhibits the reaction [[Hydrogen Peroxide results in increased activity of ALOX5 protein] which results in increased chemical synthesis of Leukotriene B4]; zileuton inhibits the reaction [ALOX5 protein promotes the reaction [lipopolysaccharide, E. coli O26-B6 results in increased abundance of Leukotriene B4]]; zileuton inhibits the reaction [ALOX5 protein results in increased susceptibility to [Histamine results in increased abundance of Leukotriene B4]] [[A 78773 co-treated with Calcimycin] results in decreased activity of ALOX5 protein] which results in decreased abundance of Leukotriene B4; [[CMI 392 co-treated with Calcimycin] results in decreased activity of ALOX5 protein] which results in decreased abundance of Leukotriene B4; [[zileuton co-treated with Calcimycin] results in decreased activity of ALOX5 protein] which results in decreased abundance of Leukotriene B4; [Calcimycin results in increased activity of and results in increased localization of ALOX5 protein] which results in increased abundance of Leukotriene B4; [lipopolysaccharide, Escherichia coli O111 B4 results in decreased activity of ALOX5 protein] which results in decreased abundance of Leukotriene B4; [tepoxalin results in decreased activity of ALOX5 protein] inhibits the reaction [Indomethacin results in increased abundance of Leukotriene B4]; [troglitazone results in decreased activity of ALOX5 protein] which results in decreased abundance of Leukotriene B4; [zileuton results in decreased activity of ALOX5 protein] inhibits the reaction [Calcimycin results in increased abundance of Leukotriene B4]; [zileuton results in decreased activity of ALOX5 protein] inhibits the reaction [Indomethacin results in increased abundance of Leukotriene B4]; [zileuton results in decreased activity of ALOX5 protein] which results in decreased abundance of Leukotriene B4; ALOX5 protein promotes the reaction [CXCL8 protein results in increased abundance of Leukotriene B4]; tetrakis(4-benzoic acid)porphyrin inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 results in decreased activity of ALOX5 protein] which results in decreased abundance of Leukotriene B4] [zileuton results in decreased activity of ALOX5 protein] which results in decreased abundance of Leukotriene B4; ALOX5 protein promotes the reaction [Ovalbumin results in increased abundance of Leukotriene B4]; zileuton inhibits the reaction [ALOX5 protein promotes the reaction [Ovalbumin results in increased abundance of Leukotriene B4]]
ALOX5AP protein results in increased susceptibility to [Histamine results in increased abundance of Leukotriene B4]; L 655238 inhibits the reaction [ALOX5AP protein results in increased susceptibility to [Histamine results in increased abundance of Leukotriene B4]]; MK-886 inhibits the reaction [ALOX5AP protein results in increased susceptibility to [Histamine results in increased abundance of Leukotriene B4]]
Leukotriene B4 results in decreased expression of BAX mRNA; Leukotriene B4 results in decreased expression of BAX protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Leukotriene B4 results in increased expression of BAX protein]; wortmannin inhibits the reaction [Leukotriene B4 results in increased expression of BAX protein]
CCL12 protein results in increased abundance of Leukotriene B4 zileuton inhibits the reaction [CCL12 protein results in increased abundance of Leukotriene B4]
Leukotriene B4 results in increased expression of CCL2 protein zileuton inhibits the reaction [CCL2 protein results in increased abundance of Leukotriene B4]
[Calcimycin co-treated with CCL5 protein] results in increased secretion of Leukotriene B4; Dexamethasone inhibits the reaction [[Calcimycin co-treated with CCL5 protein] results in increased secretion of Leukotriene B4]; Masoprocol inhibits the reaction [[Calcimycin co-treated with CCL5 protein] results in increased secretion of Leukotriene B4]
CXCL1 protein results in increased abundance of Leukotriene B4 zileuton inhibits the reaction [CXCL1 protein results in increased abundance of Leukotriene B4]
[2,3,5-trimethyl-6-(12-hydroxy-5,10-dodecadiynyl)-1,4-benzoquinone co-treated with Leukotriene B4] results in decreased expression of HSD11B2 protein; [Masoprocol co-treated with Leukotriene B4] results in decreased expression of HSD11B2 protein; Leukotriene B4 inhibits the reaction [2,3,5-trimethyl-6-(12-hydroxy-5,10-dodecadiynyl)-1,4-benzoquinone results in increased activity of HSD11B2 protein]; Leukotriene B4 inhibits the reaction [Masoprocol results in increased activity of HSD11B2 protein] Leukotriene B4 results in decreased expression of HSD11B2 mRNA Leukotriene B4 results in decreased activity of HSD11B2 protein
[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Leukotriene B4; Mangifera indica extract inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Leukotriene B4]; mangiferin inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Leukotriene B4]
IL13 protein results in increased abundance of Leukotriene B4 zileuton inhibits the reaction [IL13 protein results in increased abundance of Leukotriene B4]
IL4 protein inhibits the reaction [Calcimycin results in increased metabolism of Leukotriene B4]; IL4 protein inhibits the reaction [Zymosan affects the metabolism of Leukotriene B4]
Leukotriene B4 results in increased expression of [ITGAM protein binds to ITGB2 protein]; LY 255283 analog inhibits the reaction [Leukotriene B4 results in increased expression of [ITGAM protein binds to ITGB2 protein]]; LY 255283 inhibits the reaction [Leukotriene B4 results in increased expression of [ITGAM protein binds to ITGB2 protein]]; LY 293111 inhibits the reaction [Leukotriene B4 results in increased expression of [ITGAM protein binds to ITGB2 protein]] LTB4 increases expression of ITGAM protein on neutrophils and monocytes
Leukotriene B4 results in increased expression of ITGB2 protein Leukotriene B4 results in increased expression of [ITGAM protein binds to ITGB2 protein]; LY 255283 analog inhibits the reaction [Leukotriene B4 results in increased expression of [ITGAM protein binds to ITGB2 protein]]; LY 255283 inhibits the reaction [Leukotriene B4 results in increased expression of [ITGAM protein binds to ITGB2 protein]]; LY 293111 inhibits the reaction [Leukotriene B4 results in increased expression of [ITGAM protein binds to ITGB2 protein]]
1-(4-(benzothiazol-2-yloxy)benzyl)piperidine-4-carboxylic acid inhibits the reaction [LTA4H protein results in increased chemical synthesis of Leukotriene B4]; cyclohexene inhibits the reaction [LTA4H protein results in increased chemical synthesis of Leukotriene B4]; Oxygen inhibits the reaction [LTA4H protein results in increased chemical synthesis of Leukotriene B4]; Piperonyl Butoxide inhibits the reaction [LTA4H protein results in increased chemical synthesis of Leukotriene B4]; propanethiol inhibits the reaction [LTA4H protein results in increased chemical synthesis of Leukotriene B4]
[SC 41930 binds to and results in decreased activity of LTB4R protein] which results in decreased abundance of Leukotriene B4; Leukotriene B4 binds to and affects the activity of LTB4R1 protein Leukotriene B4 binds to and results in increased activity of LTB4R protein; LY 255283 analog inhibits the reaction [Leukotriene B4 binds to and results in increased activity of LTB4R protein]; LY 255283 inhibits the reaction [Leukotriene B4 binds to and results in increased activity of LTB4R protein]; LY 293111 inhibits the reaction [Leukotriene B4 binds to and results in increased activity of LTB4R protein] LTB4R1 protein affects the susceptibility to Leukotriene B4 Leukotriene B4 analog binds to LTB4R1 protein
Leukotriene B4 results in increased expression of MCL1 mRNA; Leukotriene B4 results in increased expression of MCL1 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Leukotriene B4 results in increased expression of MCL1 protein]; wortmannin inhibits the reaction [Leukotriene B4 results in increased expression of MCL1 protein]
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Leukotriene B4 results in increased expression of MMP9 protein]; SB 203580 inhibits the reaction [Leukotriene B4 results in increased expression of MMP9 protein]
Leukotriene B4 inhibits the reaction [[Zymosan results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitrites]
PLA2G4A protein promotes the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased metabolism of Leukotriene B4]; PLA2G4A protein promotes the reaction [Zymosan analog results in increased metabolism of Leukotriene B4]
lipoxin A4 inhibits the reaction [Ovalbumin results in increased expression of ACTA2 mRNA]; lipoxin A4 inhibits the reaction [Ovalbumin results in increased expression of ACTA2 protein]
2-(1-carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)ethylamino)-4-methylpentanoic acid inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of AGT protein alternative form]]; 7-Ala-angiotensin (1-7) inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of AGT protein alternative form]]; butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of AGT protein alternative form]]; lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of AGT protein alternative form]
[Aspirin results in increased abundance of lipoxin A4] which results in increased expression of FPR2; lipoxin A4 analog binds to and results in decreased activity of FPR2 protein lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of FPR2 mRNA] lipoxin A4 results in increased activity of FPR2
lipoxin A4 results in increased expression of HMOX1 mRNA; lipoxin A4 results in increased expression of HMOX1 protein lipoxin A4 promotes the reaction [NFE2L2 protein binds to HMOX1 enhancer]
ICAM1 protein affects the susceptibility to lipoxin A4 lipoxin A4 results in increased expression of ICAM1 protein Gentamicins inhibits the reaction [lipoxin A4 results in increased expression of ICAM1 protein]
2-(1-carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)ethylamino)-4-methylpentanoic acid inhibits the reaction [lipoxin A4 promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL10 protein]]; 7-Ala-angiotensin (1-7) inhibits the reaction [lipoxin A4 promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL10 protein]]; butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [lipoxin A4 promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL10 protein]]; lipoxin A4 promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL10 protein]
lipoxin A4 analog results in decreased expression of IL1B protein 2-(1-carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)ethylamino)-4-methylpentanoic acid inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL1B protein]]; 7-Ala-angiotensin (1-7) inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL1B protein]]; butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL1B protein]]; butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]]; butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]]; lipoxin A4 analog inhibits the reaction [TNF protein results in increased secretion of IL1B protein]; lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL1B protein]; lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein] lipoxin A4 analog results in decreased secretion of IL1B protein lipoxin A4 analog inhibits the reaction [TNF protein results in increased expression of IL1B mRNA]; lipoxin A4 analog inhibits the reaction [TNF protein results in increased secretion of IL1B protein]; lipoxin A4 inhibits the reaction [TNF protein results in increased secretion of IL1B protein]
lipoxin A4 analog results in increased secretion of IL4 protein lipoxin A4 inhibits the reaction [Ovalbumin results in increased expression of IL4 protein]
2-(1-carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)ethylamino)-4-methylpentanoic acid inhibits the reaction [[lipoxin A4 co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of MAS1 mRNA]; 2-(1-carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)ethylamino)-4-methylpentanoic acid inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of MAS1 protein]]; 7-Ala-angiotensin (1-7) inhibits the reaction [[lipoxin A4 co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of MAS1 mRNA]; 7-Ala-angiotensin (1-7) inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of MAS1 protein]]; [lipoxin A4 co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of MAS1 mRNA; butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [[lipoxin A4 co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of MAS1 mRNA]; butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of MAS1 protein]]; lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of MAS1 protein]
2-(1-carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)ethylamino)-4-methylpentanoic acid inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased activity of MPO protein]]; 7-Ala-angiotensin (1-7) inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased activity of MPO protein]]; butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased activity of MPO protein]]; lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased activity of MPO protein]
2-(1-carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)ethylamino)-4-methylpentanoic acid inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased degradation of NFKBIA protein]]; 7-Ala-angiotensin (1-7) inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased degradation of NFKBIA protein]]; butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased degradation of NFKBIA protein]]; lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased degradation of NFKBIA protein]; lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased degradation of NFKBIA protein]
butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]]; butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]
lipoxin A4 affects the reaction [PDGFB protein results in increased phosphorylation of PDGFRB protein]; PDGFB protein promotes the reaction [lipoxin A4 results in decreased phosphorylation of PDGFRB protein]
lipoxin A4 affects the reaction [PDGFB protein results in increased phosphorylation of PDGFRB protein]; lipoxin A4 inhibits the reaction [Leukotriene D4 results in increased activity of PDGFRB protein]; PDGFB protein promotes the reaction [lipoxin A4 results in decreased phosphorylation of PDGFRB protein]
[lipoxin A4 co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of PTGS2 protein; Celecoxib inhibits the reaction [PTGS2 protein affects the abundance of lipoxin A4]; lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of PTGS2 protein]
lipoxin A4 inhibits the reaction [Lipopolysaccharides affects the localization of RELA protein] 2-(1-carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)ethylamino)-4-methylpentanoic acid inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of and affects the localization of RELA protein]]; 7-Ala-angiotensin (1-7) inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of and affects the localization of RELA protein]]; butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of and affects the localization of RELA protein]]; lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of and affects the localization of RELA protein]; lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased localization of RELA protein]
AHR affects the reaction [lipoxin A4 results in increased expression of SOCS2 mRNA]; butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [lipoxin A4 results in increased expression of SOCS2 mRNA] lipoxin A4 results in increased expression of SOCS2 mRNA; lipoxin A4 results in increased expression of SOCS2 protein
lipoxin A4 results in increased expression of TGFB1 protein Gentamicins inhibits the reaction [lipoxin A4 results in increased expression of TGFB1 protein]
lipoxin A4 analog inhibits the reaction [TNF protein results in increased expression of IL1B mRNA]; lipoxin A4 analog inhibits the reaction [TNF protein results in increased secretion of IL1B protein]; lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; lipoxin A4 inhibits the reaction [TNF protein results in increased secretion of IL1B protein] Gentamicins inhibits the reaction [lipoxin A4 results in increased expression of TNF protein] 2-(1-carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)ethylamino)-4-methylpentanoic acid inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of TNF protein]]; 7-Ala-angiotensin (1-7) inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of TNF protein]]; butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of TNF protein]]; butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]; butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]]; lipoxin A4 analog inhibits the reaction [TNF protein results in increased secretion of CXCL2 protein]; lipoxin A4 analog inhibits the reaction [TNF protein results in increased secretion of IL1B protein]; lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of TNF protein]; lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]
resolvin D1 inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL2 protein]; t-butyloxycarbonyl-methionyl-leucyl-phenylalanine inhibits the reaction [resolvin D1 inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL2 protein]]
resolvin D1 analog inhibits the reaction [Paraquat results in decreased expression of HMOX1 mRNA]; resolvin D1 inhibits the reaction [Paraquat results in decreased expression of HMOX1 mRNA]
resolvin D1 inhibits the reaction [Lipopolysaccharides results in increased secretion of IFNG protein]; t-butyloxycarbonyl-methionyl-leucyl-phenylalanine inhibits the reaction [resolvin D1 inhibits the reaction [Lipopolysaccharides results in increased secretion of IFNG protein]]
resolvin D1 analog inhibits the reaction [Paraquat results in increased expression of IL1B protein]; resolvin D1 inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]
resolvin D1 inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; t-butyloxycarbonyl-methionyl-leucyl-phenylalanine inhibits the reaction [resolvin D1 inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]]
resolvin D1 analog inhibits the reaction [Paraquat results in increased activity of MPO protein]; resolvin D1 inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; resolvin D1 inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased activity of MPO protein]
resolvin D1 analog inhibits the reaction [Paraquat affects the localization of NFE2L2 protein]; resolvin D1 inhibits the reaction [Paraquat affects the localization of NFE2L2 protein]; resolvin D1 inhibits the reaction [Paraquat results in decreased expression of NFE2L2 mRNA]
resolvin D1 analog inhibits the reaction [Paraquat results in increased phosphorylation of RELA protein]; resolvin D1 inhibits the reaction [Dextran Sulfate results in increased activity of RELA protein]
resolvin D1 analog inhibits the reaction [Paraquat results in increased expression of TNF protein]; resolvin D1 inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; resolvin D1 inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; t-butyloxycarbonyl-methionyl-leucyl-phenylalanine inhibits the reaction [resolvin D1 inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]]
resolvin D2 inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; resolvin D2 inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased activity of MPO protein]
resolvin D2 inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; resolvin D2 inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]
royal jelly inhibits the reaction [Nicotine results in decreased expression of BCL2 mRNA] royal jelly inhibits the reaction [Fluorides results in increased expression of BCL2 protein]
royal jelly inhibits the reaction [Nicotine results in increased expression of CASP3 mRNA] royal jelly inhibits the reaction [Fluorides results in decreased expression of CASP3 protein]
royal jelly inhibits the reaction [Cisplatin results in decreased activity of CAT protein]; royal jelly inhibits the reaction [Fluorides results in decreased activity of CAT protein] royal jelly inhibits the reaction [Nicotine results in decreased activity of CAT protein]
Estradiol inhibits the reaction [royal jelly binds to ESR1 protein]; royal jelly binds to and results in increased activity of ESR1 protein; royal jelly inhibits the reaction [Estradiol binds to ESR1 protein] royal jelly results in increased activity of ESR1 protein
Estradiol inhibits the reaction [royal jelly binds to ESR2 protein]; royal jelly binds to and results in increased activity of ESR2 protein; royal jelly inhibits the reaction [Estradiol binds to ESR2 protein]
royal jelly inhibits the reaction [phenylhydrazine results in decreased expression of MYC mRNA] royal jelly inhibits the reaction [Paclitaxel results in decreased expression of MYC mRNA] royal jelly results in decreased expression of MYC mRNA
browse the term
